US 12,065,496 B2
Antibody molecules and conjugates
Frank Irvine Comer, Gaithersburg, MD (US); Yariv Mazor, Gaithersburg, MD (US); Srinath Kasturirangan, Gaithersburg, MD (US); Qun Du, Gaithersburg, MD (US); Chunning Yang, Gaithersburg, MD (US); and Andrew Grier Buchanan, Cambridge (GB)
Assigned to AstraZeneca AB, Sodertalje (SE)
Filed by ASTRAZENECA AB, Södertälje (SE)
Filed on Nov. 9, 2022, as Appl. No. 18/053,955.
Claims priority of provisional application 63/263,835, filed on Nov. 10, 2021.
Prior Publication US 2023/0183358 A1, Jun. 15, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 1/18 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 47/68037 (2023.08); A61K 47/6849 (2017.08); A61P 1/18 (2018.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 27 Claims
OG exemplary drawing
 
1. An antibody molecule comprising:
a first antigen-binding domain that binds epidermal growth factor receptor (EGFR); and
a second antigen-binding domain that binds c-Met,
wherein the first antigen-binding domain comprises:
(i) a heavy chain variable (VH) region comprising the following complementarity determining regions (CDRs):
HCDR1 having the amino acid sequence of SEQ ID NO: 1
HCDR2 having the amino acid sequence of SEQ ID NO: 2
HCDR3 having the amino acid sequence of SEQ ID NO: 3; and
(ii) a light chain variable (VL) region comprising the following CDRs:
LCDR1 having the amino acid sequence of SEQ ID NO: 4
LCDR2 having the amino acid sequence of SEQ ID NO: 5
LCDR3 having the amino acid sequence of SEQ ID NO: 6.